US5135920A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Angiostatic agents
Assignee: Takeda Pharmaceutical Co Ltd
•
Filing: 1989-11-09
•
Granted: 1992-08-04
•
Expires: 2009-11-09
Abstract
Abstract Dextran sulfate, β-1,3-glucan sulfate, and the salts thereof are angiostatic and useful for treatment and prevention of various diseases caused by abnormally accelerated angiogenesis. Combination of such a compound with a steroidal or non-steroidal substance increases the angiostatic activity of each compound to induce the combined effect.
Inventors
- 👤 Tsuneo Kanamaru
- 👤 Yukimasa Nozaki
- 👤 Katsuichi Sudo
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-27 05:43
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/06; A61K31/00; A61K31/56; A61K31/57; A61K31/573; A61K31/70; A61K31/715; A61K31/737; A61K45/00; A61K45/06; A61K2300/00
Claims Analysis
Total Claims: 9
Claim 1
Independent Claim
42 words
A method for prophylaxis or treatment of a disease caused by abnormally accelerated angiogenesis in a mammal, which comprises administering an angiostatic agent comprising dextran sulfate, β-1,3-glucansulfate, or a pharmaceutically acceptable salt thereof in combination with pharmaceutically acceptable carrier to the mammal.
Claim 2
Independent Claim
42 words
A method for prophylaxis or treatment of a disease caused by abnormally accelerated angiogenesis in a mammal, which comprises administering an angiostatic agent comprising dextran sulfate, β-1,3-glucansulfate, or a pharmaceutically acceptable salt thereof in combination with pharmaceutically acceptable carrier to the mammal.
Claim 3
Dependent Claim
42 words
The method according to claim 1, wherein the dextran sulfate has a mean molecular weight between about 5,000 to about 500,000 and a degree of sulfation in the dextran sulfate of about 16 to 18 weight % in terms of sulfur content.
Claim 4
Dependent Claim
70 words
The method according to claim 1, wherein the angiostatic agent is further used together with a steroidal substance which is a member selected from the group consisting of cortisone, hydrocortisone, tetrahydrocortisol, hydrocortisone-21-phosphate, 17α-hydroxyprogesterone, 11α-epihydrocortisol, cortexolon, corticosterone, desoxycorticosterone, testosterone, estrone, medroxyprogesterone and dexamethasone, or with a non-steroidal substance which is a member selected from the group consisting of a collagen synthesis inhibitor, fumagillin and fumagillin derivative, which accelerates the angiostatic activity.
Claim 5
Dependent Claim
27 words
The method according to claim 3, wherein the collagen synthesis inhibitor is a proline analog selected from the group consisting of L-azetidine-2-carboxylic acid, cis-hydroxyproline, D,L-3,4-dehydroproline and thioproline.
Claim 6
Dependent Claim
35 words
The method according to claim 3, wherein the collagen synthesis inhibitor is a specific inhibitor of collagen proline hydroxylase selected from the group consisting of P-1894B, and fibrostatin, A, B, C, D, E and F.
Claim 7
Dependent Claim
24 words
The method according to claim 1, wherein the amount of said agent administered to the mammal is 10 mg. to 900 mg. per day.
Claim 8
Dependent Claim
48 words
The method according to claim 1, wherein the β-1,3-glucan sulfate is of the formula: ##STR4## wherein n is an integer from 4 to about 1,000 and appropriate number of three hydroxyl groups of the intermediate monosaccharide units and the hydroxyl groups of the terminal monosaccharide units are sulfated.
Claim 9
Dependent Claim
36 words
The method according to claim 7, wherein the mean degree of polymerization of the β-1,3-glucan sulfate is less than 1,000 and the mean degree of substitution of the β-1,3-glucan sulfate is 0.5 to 3 per monosaccharide.
References Cited (Backward Citations)
US3754925A
Cited
US4207312A
Cited
US4793336A
Cited
US4767614A
Cited
US4833131A
Cited
US4965347A
Cited
US4840941A
Cited
US4966890A
Cited
US4820693A
Cited
US4912093A
Cited
US4921838A
Cited
EP0325199A2
Cited
US4895838A
Cited
US4876250A
Cited
US5055301A
Cited
JPH0583798A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1995-08-04 | 1996-02-03 | 1996-08-04 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1999-08-04 | 2000-02-03 | 2000-08-04 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2003-08-04 | 2004-02-03 | 2004-08-04 | $7700.00 | Window Closed / Lapsed |